RxDoctor Payments Data

David Blumenthal, MD

Cardiovascular Disease · New York, NYNPI 1427109826

Payments from drug & device makers

$4,764in general payments, 2019–2025

Across 134 payments — averaging $35.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$2K
  • Novartis$891
  • Welch Allyn$555
  • Amgen$377
  • Pfizer$272
  • Amarin Pharma, Inc.$190
  • plus $567 from 10 others

What the payments were for

  • Food & beverage$2,28848%
  • Education$80%
  • Gifts$1,91340%
  • Other$55512%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,764 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$11,086
Medicare patients
30
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis81$2,083,304
EliquisApixaban616$607,518
Repatha SureclickEvolocumab457$358,634
VyndaqelTafamidis Meglumine12$260,496
Praluent PenAlirocumab312$213,630
EntrestoSacubitril/Valsartan134$161,512
FarxigaDapagliflozin Propanediol92$103,613
JardianceEmpagliflozin87$89,679
XareltoRivaroxaban37$54,797
MultaqDronedarone Hcl22$42,044
Eplerenone361$29,412
Ezetimibe922$26,852
Rosuvastatin Calcium1,240$23,841
MounjaroTirzepatide14$21,583
NexletolBempedoic Acid28$18,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis, Vyndaqel$272$2,951,318709 claims
NovartisEntresto$891$161,512134 claims
AstraZenecaFarxiga, Brilinta, Crestor$51$131,389125 claims
Boehringer IngelheimJardiance$30$89,67987 claims
Johnson & JohnsonXarelto$60$54,79737 claims
Sanofi-aventis U.S. LLCMultaq$23$42,04422 claims
Lilly USA, LLCMounjaro$23$21,58314 claims
Esperion Therapeutics, Inc.Nexletol$61$18,02928 claims
AmgenCorlanor$377$11,72016 claims
Novo NordiskOzempic$78$9,97211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →